Enanta Pharmaceuticals (ENTA) Research & Development (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Research & Development came in at $19.4 million in Q1 2026, down 30.72% YoY from $28.1 million in Q1 2025, and down 6.79% on a QoQ basis from $20.9 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) Research & Development (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of Research & Development data on file, last reported at $19.4 million in Q1 2026.
- Quarterly Research & Development fell 30.72% year-over-year to $19.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $91.3 million (down 20.76% YoY) and the FY2025 annual result came in at $106.7 million, down 18.81% from the prior year.
- Research & Development declined to $19.4 million in Q1 2026, from $20.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $43.5 million in Q1 2023 to a low of $19.4 million in Q1 2026.
- A 5-year average of $32.8 million and a median of $34.8 million in 2022 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development grew 9.97% — and 2024, when it tumbled 33.14%.
- Tracing ENTA's Research & Development over 5 years: stood at $40.9 million in 2022, then retreated by 11.08% to $36.4 million in 2023, then declined by 23.96% to $27.7 million in 2024, then slipped by 24.58% to $20.9 million in 2025, then dropped by 6.79% to $19.4 million in 2026.
- The last three Research & Development figures came in at $19.4 million (Q1 2026), $20.9 million (Q4 2025), and $23.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | 22.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.13 Mn |
| Mar 31, 2026 | 19.44 Mn |
| Dec 31, 2025 | 20.86 Mn |
| Sep 30, 2025 | 23.81 Mn |
| Jun 30, 2025 | 27.21 Mn |
| Mar 31, 2025 | 28.07 Mn |
| Dec 31, 2024 | 27.66 Mn |
| Sep 30, 2024 | 30.78 Mn |
| Jun 30, 2024 | 28.74 Mn |
| Mar 31, 2024 | 35.59 Mn |
| Dec 31, 2023 | 36.37 Mn |
| Sep 30, 2023 | 36.17 Mn |
| Jun 30, 2023 | 42.99 Mn |
| Mar 31, 2023 | 43.47 Mn |
| Dec 31, 2022 | 40.90 Mn |
| Sep 30, 2022 | 34.80 Mn |
| Jun 30, 2022 | 39.09 Mn |
| Mar 31, 2022 | 42.09 Mn |
| Dec 31, 2021 | 48.55 Mn |
| Sep 30, 2021 | 48.95 Mn |